

SCIENTIFIC REPORTS



OPEN

First insight into the proteome landscape of the porcine short posterior ciliary arteries: Key signalling pathways maintaining physiologic functions

Received: 06 September 2016

Accepted: 07 November 2016

Published: 06 December 2016

Caroline Manicam, Natarajan Perumal, Norbert Pfeiffer, Franz H. Grus & Adrian Gericke

Short posterior ciliary arteries (sPCA) provide the major blood supply to the optic nerve head. Emerging evidence has linked structural and functional anomalies of sPCA to the pathogenesis of several ocular disorders that cause varying degrees of visual loss, particularly anterior ischaemic optic neuropathy and glaucoma. Although the functional relevance of this vascular bed is well-recognized, the proteome of sPCA remains uncharacterized. Since the porcine ocular system closely resembles that of the human's and is increasingly employed in translational ophthalmic research, this study characterized the proteome of porcine sPCA employing the mass spectrometry-based proteomics strategy. A total of 1742 proteins and 10527 peptides were identified in the porcine sPCA. The major biological processes involved in the maintenance of physiological functions of the sPCA included redox and metabolic processes, and cytoskeleton organization. These proteins were further clustered into diverse signalling pathways that regulate vasoactivity of sPCA, namely the tight junction, α - and β -adrenoceptor, 14-3-3, nitric oxide synthase and endothelin-1-mediated signalling pathways. This study provides the first insight into the complex mechanisms dictating the vast protein repertoire in normal vascular physiology of the porcine sPCA. It is envisioned that our findings will serve as important benchmarks for future studies of sPCA.

Short posterior ciliary arteries (sPCA) are the major blood suppliers to the optic nerve head (ONH). In humans, the sPCA arise from the medial branching of the ophthalmic artery, which emerges from the internal carotid artery¹⁻³. Circulatory insufficiency in these retrobulbar blood vessels constitute one of the crucial contributing factors to the pathogenesis of several vision threatening ocular disorders, especially anterior ischaemic optic neuropathy (AION) and glaucomatous optic neuropathy (GON)⁴⁻⁸. The global burden of visual impairment due to glaucoma is projected to escalate by the year 2040, with almost 111.8 million of the world population affected by this second leading cause of blindness and 11.1 million of these are estimated to be bilaterally blind⁹⁻¹². Likewise, up to 82 in 100 000 individuals are estimated to suffer from the most common type of AION, non-arteritic anterior ischemic optic neuropathy (NAION) annually^{13,14}. Over the years, mounting evidence has associated these debilitating ocular diseases with hemodynamic alterations in the ONH¹⁵⁻¹⁷. Although elevated intraocular pressure (IOP) has been identified as the primary disease factor for glaucoma, its pathogenesis still remains a topic of much challenge in ophthalmic research owing to myriad other risk factors that may eventually cause optic nerve and retinal dysfunctions, regardless of the IOP^{5,18,19}. It has been suggested that treatment options which increase ONH perfusion may facilitate clinical management of GON more effectively²⁰.

The study of the pathogenesis of GON has made some progress in recent years with the use of animal models and genomic tools^{21,22}. Although molecular technologies have profoundly facilitated the discovery of gene expression profiles in disease conditions, it is the effectors i.e. proteins that are the major players which regulate normal physiological functions. Therefore, proteomics, the protein cognate of genomics, has emerged as a powerful tool to characterize the protein expressions, post-translational modifications and to identify candidate disease

Department of Ophthalmology, University Medical Centre of the Johannes Gutenberg University Mainz, Mainz, Germany. Correspondence and requests for materials should be addressed to C.M. (email: cmjc_82@yahoo.com)




Figure 1. The porcine short posterior ciliary arteries. Photograph showing the short posterior ciliary arteries that enter the eye globe close to the optic nerve.

biomarkers in pathological states compared to normal condition. Nevertheless, there is a paucity of information on the cellular signalling mechanisms underlying perturbed ocular microcirculation. A confounding challenge in ophthalmic research is the limited availability of human tissue samples for analysis. Therefore, it is important to employ samples from animal models that closely resemble those of human's for highly translational results. In light of this, porcine ocular tissues were used in this study due to the high phylogenetic and morphological similarities to the human eye²³. For decades, the pig has become an animal model of choice in biomedical research to study various human pathologies, including vascular functions in disease conditions compared to healthy controls^{24,25}. Additionally, the pig eye is commonly used in vision research and is also a validated animal model to study glaucoma²⁶.

Considering the functional relevance and importance of the sPCA in the perfusion of ONH and, the dearth of studies investigating the molecular regulators that maintain physiological functions in ocular blood vessels, this is the first study to characterize the fundamental cellular signalling mechanisms employing the mass-spectrometry-based proteomics approach. It is projected that the findings emerging from this study will provide an in-depth mechanistic insight into the complex cell signalling pathways that orchestrate circulatory functions in the sPCA and furnish vital information at the protein level. Finally, the methodology employed in this investigation, particularly catered for optimum protein extraction and proteome characterization of ocular blood vessels, is envisaged to be instrumental for future studies utilizing other ocular vascular beds.

Results

Identification of porcine sPCA proteins. This study endeavoured to profile the proteome of porcine sPCA (Fig. 1). The experimental workflow overview of this study is depicted as a schematic representation in Fig. 2. A total of 1742 proteins and 10 527 peptides were identified with a false discovery rate (FDR) of less than 1% after removal of reverse hits (Supplementary Table S1). The protein profiles of this vascular bed resolved in one-dimensional gel electrophoresis (1DE) is as depicted in Fig. 3a. With the approach of intensity-based absolute quantification (iBAQ), the relative abundance of the identified proteins was estimated. Of the 1742 proteins identified, the five most abundant proteins comprise 50% of the proteome, while 38 most abundant proteins accounted for 75% of the porcine sPCA proteome (Fig. 3b, Table 1).

Proteomic profiles and functional annotations of sPCA. The classification of the identified sPCA proteins was performed employing the Ingenuity Pathways Analysis software (IPA, Ingenuity QIAGEN Redwood City, CA) (www.qiagen.com/ingenuity), DAVID tool (version 6.7) (<http://david.abcc.ncifcrf.gov/home.jsp>) and Protein ANALysis THrough Evolutionary Relationships (PANTHER, <http://pantherdb.org>) functional annotation tools. First, the analysis of the major Gene Ontology Cellular Component terms (GOCCs) employing IPA demonstrated that the top four subcellular localizations of the sPCA proteins corresponded to cytoplasm (56%), while almost 14% and 10% of the total proteins are from the nucleus and plasma membrane, respectively. Only a small percentage (9%) of the total proteins was localized in the extracellular space, while the remaining 11% comprises unknown and other proteins, as shown in Supplementary Fig. S1. Next, to assess the biological




Figure 2. Workflow overview for mapping of the porcine sPCA proteome. Freshly isolated porcine sPCA were pooled equally into three biological replicates, represented by R1, R2 and R3. Samples were extracted with T-PER tissue protein extraction reagent and subjected to 1DE gel electrophoresis. The protein bands were sliced and trypsin-digested prior to proteomic analysis by LC-MS/MS. Finally, the emerging datasets were subjected to robust bioinformatics analyses and functional annotations of the significant gene ontology (GO) terms and pathways employing various tools to produce a comprehensive map of the normal porcine sPCA proteome.




Figure 3. Proteomics analysis employing the 1DE & LC-ESI-MS/MS strategy reveals the inherent characteristics of the porcine sPCA. (a) Representative protein profiles of the sPCA resolved in 1DE gel after colloidal blue staining. (b) Quantitative analysis employing iBAQ shows the cumulative relative abundance of identified proteins, ranked from the highest to the lowest abundance.

relevance of the identified proteins, enrichment analysis employing DAVID was performed. These proteins were classified into 626 distinct categories of GO Biological Process (GOBPs) terms, with 227 significant processes ($p < 0.001$) involved in the maintenance of physiological functions in the sPCA (Supplementary Table S2). Figure 4 shows that the top twenty significant biological processes comprise proteins which are mainly involved in oxidation-reduction processes (133 proteins), generation of precursor metabolites and energy (112 proteins) and 87 proteins in cytoskeleton organization. Six clusters of proteins were involved in various catabolic processes, composed of the carbohydrate (37 proteins), cellular carbohydrate (35 proteins), alcohol (34 proteins), monosaccharide (32 proteins), hexose and glucose (30 proteins each) catabolic processes. Another two clusters

Rank	Protein Name	Gene Name	Peptides	Sequence Coverage (%)	iBAQ
1	Hemoglobin subunit beta	HBB	17	84.37	4.09E+09
2	Hemoglobin subunit alpha	HBA	12	87.03	3.00E+09
3	Uncharacterized protein	LOC100302368	8	45.50	2.65E+09
4	Cardiac muscle alpha actin 1	ACTC1	33	81.23	2.23E+09
5	Serum albumin	ALB	69	82.37	1.96E+09
6	Ig lambda chain C region	N/A	7	92.40	5.77E+08
7	Uncharacterized protein	LUM	15	47.30	5.16E+08
8	Transgelin	TAGLN	20	76.27	4.78E+08
9	Uncharacterized protein (Fragment)	N/A	5	80.70	4.06E+08
10	Protease serine 1 (Fragment)	PRSS1	1	23.80	3.74E+08
11	Actin, cytoplasmic 2	ACTG1	29	80.00	3.63E+08
12	Decorin	DCN	21	58.97	3.11E+08
13	IgG heavy chain	IGHG	18	51.33	2.66E+08
14	IgG heavy chain	IGHG	17	45.97	2.33E+08
15	Galectin	LGALS1	9	75.80	2.17E+08
16	Serotransferrin	TF	57	78.70	2.16E+08
17	Tropomyosin 1 (Alpha), isoform CRA	TPM1	33	61.43	2.03E+08
18	Osteoglycin/mimecan	OGN	16	44.50	1.86E+08
19	Vimentin	VIM	35	71.83	1.77E+08
20	S-arrestin	SAG	27	82.80	1.67E+08
21	Protein S100-A1	S100A1	2	38.30	1.63E+08
22	Uncharacterized protein	CA2	20	71.63	1.59E+08
23	Creatine kinase B-type	CKB	13	75.00	1.50E+08
24	Glyceraldehyde-3-phosphate dehydrogenase	GAPDH	20	70.60	1.47E+08
25	Protein S100	S100B	3	40.20	1.41E+08
26	Triosephosphate isomerase	TPI1	18	83.63	1.29E+08
27	Actin alpha 2	ACTA2	33	81.23	1.27E+08
28	Phosphatidylethanolamine-binding protein 1	PEBP1	15	79.10	1.26E+08
29	Cysteine and glycine-rich protein 1	CSRP1	11	56.00	1.24E+08
30	Synaptotagmin-7	SYT7	1	6.60	1.23E+08
31	Annexin A2	ANXA2	28	72.60	1.18E+08
32	Uncharacterized protein	TPM2	29	64.30	1.16E+08
33	Creatine kinase M-type	CKM	22	59.67	1.12E+08
34	Uncharacterized protein	ENO1	18	55.83	1.09E+08
35	Myosin light chain 1/3, skeletal muscle isoform	MYL1	16	78.30	1.07E+08
36	Annexin	ANXA5	24	74.60	1.06E+08
37	Glutathione S-transferase	GSTP1	11	61.23	1.03E+08
38	Filamin-A	FLNA	116	56.27	1.03E+08

Table 1. Top 38 most abundant proteins in the porcine sPCA.

were responsible for electron transport chain and the remaining clusters were implicated in protein folding, translational elongation, oxidative phosphorylation, glucose metabolism and glycolysis. In the category of GO molecular types analysed employing IPA, almost 30% of the total proteins function as enzymes, transporters (7.18%), peptidases (4.25%), transcription regulators (3.46%), kinases (2.94%) and phosphatases (2.22%), while an approximately 38% proteins were assigned into the category of other molecular types, as depicted in Fig. 5a. The molecular identity of these 'other' proteins were further dissected employing the DAVID analysis tool and the highly significant ($p < 0.001$) ones largely represented proteins involved in structural molecule activities (16%), cytoskeletal protein, actin, RNA, calcium ion, unfolded protein, collagen, integrin, extracellular matrix, enzyme and calmodulin binding (13, 11, 9, 10, 3, 1, 2, 1, 5 and 2%, respectively) and other structural constituents (11%), as shown in Fig. 5b.

Pathway and protein networks analysis. The identified proteins were analysed with PANTHER to classify them according to associated canonical pathways and the pathways that exhibited significant values were distinguished. The following are the notably significant ($p < 0.001$) pathways implicated in the porcine sPCA (numbers in brackets indicate the number of proteins identified in each pathway and the p value), as demonstrated in Fig. 6: Integrin signalling pathway (59; $p = 1.37E-09$), Huntington disease pathway (36; $p = 3.62E-04$), cytoskeletal regulation by Rho GTPase (34; $p = 2.45E-07$), Parkinson disease pathway (32; $p = 5.27E-07$), dopamine receptor mediated signalling pathway (24; $p = 1.86E-04$), metabotropic glutamate receptor group II pathway




Figure 4. Functional classification of the sPCA proteome associated with over-represented GOBP terms. Top twenty significantly ($p < 0.001$) enriched biological processes involved in the proper functionality of the porcine sPCA analysed employing the DAVID tool.




Figure 5. Functional classification of the sPCA proteome associated with over-represented GO molecular type terms. (a) Data presented as a bar chart of proteins clustered according to their molecular types analysed employing IPA database. (b) Further analysis of the molecular identity of the proteins categorised as ‘others’, represented by stacked bar chart of the most significant ($p < 0.001$) molecular functions as analysed by DAVID tool.




Figure 6. Functional classification of the sPCA proteome according to enriched canonical pathways. Eleven functional and disease pathways were significantly ($p < 0.001$) implicated in the proteome of sPCA, identified employing the PANTHER tool.




Figure 7. Canonical pathways involved in vasoactivity of the sPCA. This bar chart shows the canonical pathways which were significantly ($p < 0.001$) implicated in the vasoactivity of the sPCA, analysed employing IPA. The negative of the \log_{10} (p-value; bar chart) and ratio (number of focus molecules involved in the pathway/total number of molecules in the pathway; solid line joined by circles) are plotted on the primary and secondary Y-axes, respectively.

(20; $p = 4.64E-06$), muscarinic acetylcholine receptor 2 and 4 signalling pathway (20; $p = 2.86E-05$), 5HT1 type receptor mediated signalling pathway (16; $p = 2.14E-04$), enkephalin release (15; $p = 2.64E-05$), glycolysis (14; $p = 2.55E-06$) and histamine H2 receptor mediated signalling pathway (11; $p = 8.04E-04$).

Next, the proteins identified in the present study were analysed employing the IPA database to characterize pathways which are responsible for vasoactivity. To determine the p-values for protein datasets within the predetermined canonical pathways, the significance was calculated employing Benjamini-Hochberg corrected Fisher's exact test, and the ratio represented the number of molecules in the dataset associated with a particular pathway to the total number of molecules in that pathway. The top significant ($p < 0.05$) pathways which are implicated in the maintenance of vasoactivity of the sPCA are shown in Fig. 7 and these included tight junction signalling ($p = 1.26E-13$; ratio = 0.25), α -adrenergic signalling ($p = 2.04E-10$; ratio = 0.29), gap junction signalling ($p = 2.51E-021$; ratio = 0.21), cardiac β -adrenergic signalling ($p = 5.01E-08$; ratio = 0.21), noradrenaline and adrenaline degradation ($p = 1.29E-07$; ratio = 0.35), 14-3-3-mediated signalling ($p = 3.16E-07$; ratio = 0.20), vascular endothelium growth factor (VEGF) signalling ($p = 3.09E-06$; ratio = 0.20), endothelial nitric oxide synthase




Figure 8. Protein interaction networks of merged vasoactive pathways in the sPCA. The significantly ($p < 0.001$) expressed vasoactive pathways were merged to elucidate their PPI networks. The different shapes of the nodes indicate the gene or gene products of the annotated proteins and the relationship between nodes is represented as an edge (line).

(eNOS) signalling ($p = 2.19\text{E-}04$; ratio = 0.15), nitric oxide signalling in the cardiovascular system ($p = 4.27\text{E-}04$; ratio = 0.16), renin-angiotensin signalling ($p = 1.26\text{E-}02$; ratio = 0.13), endothelin-1 signalling ($p = 2.24\text{E-}02$; ratio = 0.11), nNOS signalling in neurons ($p = 3.31\text{E-}02$; ratio = 0.15) and G-protein coupled receptor signalling ($p = 3.47\text{E-}02$; ratio = 0.10). Figure 8 is a schematic overview of the interplay between all significant pathways mediating vasoactivity in sPCA, which were merged to observe their protein-protein interactions (PPI). A high number of interactions were found to be clustered in actin cytoskeleton organization and various cellular processes, including cell proliferation, differentiation, apoptosis, migration, cell cycle progression and tight junction permeability. Additionally, there are some transport proteins involved in exocytosis and vesicle trafficking. Interestingly, the renin-angiotensin signalling has the highest PPI, followed by the gap junction and VEGF pathways. Among the interacting proteins, the tight junction protein 1 (*ZO1*) has the highest number of interactions (10 PPI) with other proteins, followed closely by cingulin (*CGN*) with 8 PPI, atypical protein kinase C (*aPKC*) and occludin (*OCLN*) with 6 PPI each and, tight junction protein 2 (*ZO2*) with 5 PPI. In addition to PPI, most proteins namely *CGN*, *aPKC* and *ZO2* also exhibited inhibitory action on other proteins, while some proteins such as par-6 family cell polarity regulator alpha (*PAR6*), symplekin (*SYMP*) and membrane-associated guanylate kinase (*MAGI-2*) activated other proteins. Full details of the proteins and their interactions in the merged vasoactive signalling pathways can be found in Supplementary Table S3.

Discussion

The present study provides the first insight into the complexity of the porcine sPCA proteome, represented by 1742 proteins and 10 527 peptides. The clinical and functional studies of sPCA have gained immense interest in recent years attributed to several lines of evidence that link compromised blood flow in these retrolubar vessels to debilitating ocular pathologies, especially in glaucoma and NAION^{2,6,19}. It is of interest to note that among the numerous signalling pathways identified in sPCA in this study, the top four most significantly detected comprised the integrin, Huntington disease, Rho GTPase and Parkinson disease-related pathways.

Blood vessels are highly dynamic circulatory organs that undergo constant structural and functional adaptations, called vascular remodelling, in response to various stimuli, specifically pulsatility of blood flow and pressure^{27,28}. This remodelling process involves many crucial physiological mechanisms comprising cell-matrix and cell-to-cell communication, which are mediated primarily by integrins that act as cell adhesion receptors^{29,30}. It is therefore not surprising that the integrin signalling complexes are referred to as ‘master regulators’ of cellular functions³¹. Integrins are membrane-spanning ubiquitous proteins that orchestrate a wide variety of cellular functions, as well as a myriad of intracellular signalling pathways^{30,32}. In vascular cells, integrins are key protein entities that have established roles in mechanotransduction to detect and respond to shear stress and pressure, and consequently modify vascular tone to compensate for environmental changes and effectively restore normal vascular functions³³. Furthermore, endothelial and vascular smooth muscle integrins have emerged as attractive therapeutic candidates for an array of vasculopathies³². In respect to integrins’ translational potential in the

clinical settings, there is an upsurge of interest in the ocular research community in the role played by these transmembrane glycoproteins in the pathogenesis of glaucomatous optic neuropathy (GON)^{34–36}.

On the other hand, integrins are also closely associated with Rho family GTPase in modulating junctional integrity in vascular endothelial cells and in signal transduction for cytoskeletal organization^{37–39}. Vascular permeability is tightly regulated under physiological conditions by intercellular tight junctions and vascular endothelial growth factor (VEGF), which work in concert with Rho-GTPases to form semipermeable paracellular barriers that control passage of solutes and also maintain cell polarity^{40–42}. Correspondingly, the findings from the current study have also demonstrated that the tight junction and VEGF signalling pathways were implicated in the maintenance of vasoactivity of the sPCA (Fig. 7). Apart from regulating diverse cellular functions to maintain physiological integrity, the Rho family GTPases are intimately implicated in maintaining vascular homeostasis⁴³. In blood vessels, the Rho/Rho-associated protein kinase (ROCK) pathway is expressed abundantly in the vascular smooth muscle and is known to regulate vasoreactivity^{44,45}. Noteworthy in this context is that this family of proteins is recognized as key signalling molecules that regulate arterial blood pressure and are important mediators involved in maintaining vascular tone in pathophysiological conditions, such as hypertension^{46,47}. Hence, any alterations in the hemodynamic balance and level of activation of the Rho protein family members may compromise the vascular integrity and lead to various vasculopathies^{43,48}. It is well-known that the ROCK inhibitors are able to relax vascular smooth muscle cells and may enhance ocular blood flow⁴⁹. As such, the Rho/ROCK signalling pathway has emerged as a promising druggable target to treat GON because one of the major causative factors of blindness in glaucoma is recognized to arise from perturbed perfusion at the level of optic nerve head^{50–52}.

It is intriguing that apart from identification of proteins involved in the organization of cytoskeleton and maintenance of cellular functions, two other clusters of proteins involved in neurodegenerative disease signalling pathways, the Huntington and Parkinson's disease, were also identified with high significance in the porcine sPCA. A large proportion of the proteins identified in the Parkinson's disease pathway consisted of 14-3-3, proteasomes and to a lesser extent, heat shock protein (HSP) 70 kDa and synucleins (Supplementary Table S4). The regulation of 14-3-3 family of proteins is tightly controlled in normal cellular milieu and implicated in a broad spectrum of both general and specialized signalling pathways, indicating their pivotal roles in health and disease^{53,54}. Albeit their 'global' roles in cell cycle and programmed cell death, as well as in protein trafficking in multiple tissue types, these proteins are found most abundantly in neurons of the brain and are associated with the pathogenesis of neurodegenerative disorders, namely Parkinson's disease^{55–57}. Consistent with this, a study by Yacoubian *et al.* employing cellular and animal models of Parkinson's disease has demonstrated that binding impairment of multiple isoforms of 14-3-3 to α -synuclein led to toxicity in dopaminergic neurons⁵⁸. Interestingly, the 14-3-3-mediated signalling was found to have significant role(s) in the vasomotricity of sPCA in the present study, although the exact mechanism(s) how this signalling network functions in this vascular bed remains to be determined. Basal levels of 14-3-3 isoforms were also detected in other arterial beds such as in the healthy human coronary arteries, with potential function in vascular smooth muscle activation and response to arterial injury⁵⁶. Conversely in disease conditions, for example in diabetic animals with occlusion of the middle cerebral artery, the expression of 14-3-3 proteins was diminished and this exacerbated brain damage⁵⁹. It is well-recognized that the plasticity of the vascular smooth muscle cells is a pivotal adaptation mechanism to physiological and environmental changes, including cell proliferation, extracellular matrix organization and apoptosis^{60,61}. Since one of the primary functions of this protein family is to antagonize apoptotic signals and thereby, inhibit cell death⁶², the expression levels of the 14-3-3 proteins in porcine sPCA in the current study conceivably reflect its functional relevance in the maintenance of vascular integrity in normal physiological state. It is noteworthy that in the ocular system, abnormalities of 14-3-3-mediated signalling are related to the pathogenesis of glaucoma⁶³.

A plethora of proteasome isoforms were also found in the Parkinson's disease pathway in the porcine sPCA. This multifaceted ubiquitous proteinase governs a wide array of intracellular functions, with particular function in degradation of damaged proteins^{64,65}. In a study employing normal animals, the inhibition of proteasome system proved lethal and led to the development of vasculopathy, where altered microvascular permeability and cardiac apoptosis were observed, to name a few detrimental effects of proteasome dysfunction⁶⁶. Additionally, angiogenesis is regulated through proteasome and any deleterious changes in its functional activity will affect the formation of blood vessels^{67,68}. On the other hand, given the vital regulatory role of redox signalling in various vascular smooth muscle cell patho(biology), also as evidenced by the significantly high expression of proteins involved in the oxidation-reduction activities in the porcine sPCA (Fig. 4), it is not wrong to conceptualize the importance of interplay between the ubiquitin-proteasome system and cellular redox processes⁶⁹. The oxido-reductive signalling plays integral roles in vascular remodelling processes, importantly in the regulation of cytoskeletal dynamics and modulation of smooth muscle cell differentiation^{27,70}. Concomitant identification of actin-related complexes and tubulins in the Huntington disease pathway in the current exploratory study comes as no surprise as these are arguably among the most overwhelmingly expressed proteins in cells, which assemble to construct complex networks of cytoskeleton^{71,72}, and this is in agreement with the significant detection of the actin-cytoskeleton processes in the porcine sPCA (Fig. 4). It goes without saying that any cytoskeletal aberrations are therefore, responsible for cellular contractile dysfunction⁷³.

Interestingly, the proteomic findings emerging from the present study on the pathways involved in the vasoactivity of the porcine sPCA not only provide novel insight at the protein level, but are also in agreement with previous *in vivo* and *in vitro* studies carried out with pharmacological approaches. In retrospect, studies have demonstrated that the α_1 -adrenergic and 5-HT receptors are responsible for mediating vasoconstriction, while the β -adrenergic receptors mediated vasodilation in the human posterior ciliary arteries^{74,75}. This corroborates with the detection of both α - and β -adrenergic, and 5-HT receptor-mediated signalling pathways with high significance in the current study. Likewise, the endothelin-1 (ET-1) signalling was also significantly detected in this investigation and this protein signalling has been associated with the pathogenesis of glaucoma, regardless of the intraocular pressure. Perturbances in the blood flow velocity were found primarily in the retrobulbar vasculature

of glaucoma patients, with most pronounced changes in the sPCA⁷. ET-1 signalling is not only implicated in the regulation of smooth contraction, but also functions as an important mediator in inflammation^{76,77}. On the other hand, neuronal mediators of vasoactivity comprising the muscarinic acetylcholine receptor (Chrm) 2 and 4 signalling pathways were also detected in this ocular vascular bed in the present investigation. Both receptor subtypes selectively activate the G-proteins of the G_i/G_o family⁷⁸. Studies carried out with Chrm 2^{-/-} mice strongly suggest that Chrm 2 is the predominant autoreceptor that mediates cortical and hippocampal release of acetylcholine^{79,80}. Since the sPCA are autonomically innervated, acetylcholine released from the cholinergic nerves seemed to modulate nitroxidergic nerve functions in porcine ciliary arteries^{74,75}. Presynaptic Chrm 2 was also identified in the mouse cerebral arteries and was implicated in neurogenic vasoconstriction *via* inhibition of nitric oxide synthase (NOS)⁸¹. Consistent with this mechanism, several NOS pathways were also found to be significantly expressed in the porcine sPCA in this study. Besides, this Chrm subtype was also known to exert anti-apoptotic effects on cardiomyocytes and mediate antinociception^{78,82}.

Taken together, the vascular integrity of the porcine sPCA is maintained by a plethora of highly dynamic protein networks that ensure proper vessel functionality and physiology, as evidenced by this study. For the first time, the expanding paradigm of exploratory proteomics has provided a sophisticated and unbiased approach to unravel the biological processes governing fundamental cell functions in a retrobulbar vascular bed at the protein level. However, a limitation of the present study is that the proteins identified from the sPCA cannot be particularly ascribed to the different layers that make up the blood vessels i.e. the adventitia, vascular smooth muscle and endothelial cells. It would be therefore interesting to further elucidate, compare and contrast the proteome of the major layers of the sPCA in future investigations utilizing the proteomic and bioinformatics platform established in this study. In conclusion, the findings emerging from our study are envisaged to serve as important benchmark and database for future studies employing porcine sPCA.

Materials and Methods

Animals. All experiments were conducted in adherence to the Association for Research in Vision and Ophthalmology (ARVO) Statement for the Use of Animals in Ophthalmic and Vision Research and by institutional guidelines. The study was conducted and approved at the Department of Ophthalmology, University Medical Centre Mainz. Fresh eyes from pigs (Piétrain breed) approximately 3–6 months old were obtained from a local abattoir immediately post-mortem. The enucleated eyes attached with optic nerve and extraocular tissues were transported to the laboratory in ice-cold Krebs-Henseleit buffer at pH 7.4 with the following ionic composition in mM: 118.3 NaCl, 4.7 KCl, 2.5 CaCl₂, 1.2 MgSO₄, 1.2 KH₂PO₄, 25 NaHCO₃, and 11 glucose (Carl Roth GmbH, Karlsruhe, Germany).

Protein extraction from sPCA. The porcine ciliary arterial branches are divided into the short and long posterior ciliary arteries, as described elsewhere^{83–85}. Therefore, to standardize the isolation procedure, the arterial branch used in the current study was restricted to the paraoptic sPCA that travel along the optic nerve to enter the eye globe, as shown in Fig. 1. The luminal diameter of the isolated vessels is between 130 and 250 μm. Branches of the sPCA were carefully dissected and cleaned of connective tissues using fine-point tweezers under a dissecting microscope. Thereafter, the isolated blood vessels were gently rinsed in ice-cold phosphate buffered saline (PBS) to remove any blood contaminants and were used for proteomic analysis. The sPCA from five pigs were pooled (which constituted one biologic replicate) and a total of three biological replicates were used in this study. Protein extraction from the porcine sPCA was carried out employing T-PER Tissue Protein Extraction Reagent (Thermo Scientific Inc., Waltham, MA, USA) according to the manufacturer's instruction with slight modifications. Briefly, the isolated sPCA were weighed immediately after isolation and cleaning, followed by protein extraction with 10 ml T-PER reagent added to 0.5 g samples. Subsequently, the vascular samples in T-PER reagent were homogenized employing the BBY24M Bullet Blender Storm (Next Advance Inc., Averill Park, NY, USA) and centrifuged at 10,000 × g for 5 minutes to pellet the tissue debris. The supernatant was collected and subjected to sample cleaning employing the Amicon Ultra 0.5 mL centrifugal filters with 3 K cutoff (Merck Millipore, Carrigtwohill, Ireland). The protein concentration of the obtained eluate was determined using BCA Protein Assay Kit (Pierce, Rockford, IL).

1DE. The sPCA eluates were subjected to 1DE (50 μg sample per well) using 4–12% Bis-Tris Gels (Invitrogen, Karlsruhe, Germany) with MOPS running buffer under reducing conditions for 60 min with a constant voltage of 150 V, according to the manufacturer's instructions. The SeeBlue Plus 2 (Invitrogen, Karlsruhe, Germany) pre-stained protein standard was used as a molecular mass marker. Next, the gels were stained with Colloidal Blue Staining Kit (Invitrogen, Karlsruhe, Germany) according to the manufacturer's instructions. Then, protein bands (sliced into 39 bands per replicate) were cut into small pieces and subjected to dehydration utilizing neat acetonitrile prior to disulfide bonds cleavage with 10 mM 1,4-Dithiothreitol (DTT) in 100 mM ammonium bicarbonate (NH₄HCO₃) and alkylation with 55 mM iodoacetamide (IAA) in 100 mM NH₄HCO₃. The reduced and alkylated protein mixtures were digested with sequence grade-modified trypsin (Promega, Madison, USA) resuspended in 10 mM NH₄HCO₃ and 10% acetonitrile for 16 h at 37 °C. Subsequently, proteolysis was quenched by acidification of the reaction mixtures with 100 μl of extraction buffer composed of 1: 2 (vol/vol) of 5% formic acid: acetonitrile and, incubated for 15 min at 37 °C in a shaker. The supernatant containing peptides was collected and the remaining peptides in the gel pieces were extracted with two 20 minutes washes in extraction buffer. The supernatants were pooled and concentrated to dryness in SpeedVac (Eppendorf, Darmstadt, Germany) prior to storage at -20 °C^{86,87}. Next, the peptides recovered from the in-gel digestion were subjected to purification employing ZipTip C18 columns (Millipore, Billerica, MA, USA) according to the manufacturer's instructions. This peptide-purification procedure was repeated four times for each sample and the combined eluate was dried in the SpeedVac, dissolved in 10 μL of 0.1% trifluoroacetic acid (TFA) solution prior to LC-MS/MS analysis.

LC-ESI-MS/MS. The LC-ESI-LTQ-Orbitrap MS system is well established in our laboratory and details of this system are described in detail elsewhere^{86,88,89}. Briefly, solvent A which consisted of LC-MS grade water with 0.1% (v/v) formic acid, and solvent B consisting of LC-MS grade acetonitrile with 0.1% (v/v) formic acid were utilized. The gradient was run for 90 min per gel spot as follows; 0–50 min: 10–35% B, 50–70 min: 35–55% B, 70–75 min: 55–90% B, 75–80 min: 90% B, 80–83 min: 90–10% B und 83–90 min: 10% B. Continuum mass spectra data were acquired on an ESI-LTQ-Orbitrap-XL MS (Thermo Scientific, Bremen, Germany) and the general mass spectrometric conditions were as follows: positive-ion electrospray ionization mode, spray, capillary and the tube lens voltages were set at 4.5 kV, 48 V and 120 V, respectively, and the heated capillary temperature was set at 275 °C. The LTQ-Orbitrap was operated in a data-dependent mode of acquisition to automatically switch between Orbitrap-MS and LTQ-MS/MS acquisition. Survey full scan MS spectra (from m/z 300 to 2000) were acquired in the Orbitrap with a resolution of 30000 at m/z 400 and a target automatic gain control (AGC) setting of 1.0×10^6 ions. The lock mass option was enabled in MS mode and the polydimethylcyclsiloxane (PCM) m/z 445.120025 ions were used for internal recalibration in real time⁹⁰. The five most intense precursor ions were sequentially isolated for fragmentation in the LTQ with a collision-induced dissociation (CID) fragmentation, the normalized collision energy (NCE) was set to 35% with activation time of 30 ms with repeat count of 3 and dynamic exclusion duration of 600 s. The resulting fragment ions were recorded in the LTQ.

Bioinformatics and Gene Ontology (GO) functional annotation analysis. The acquired continuum MS datasets were analysed by MaxQuant (version 1.5.2.8, <http://www.maxquant.org/>) computational proteomics platform and its built-in Andromeda search engine for peptide and protein identification, with iBAQ algorithm enabled^{91–94}. The tandem MS spectra were searched against UniProtSP/TrEMBL (*Homo sapiens* and *Sus scrofa* database (date: 1st July 2016) using standard settings with peptide mass tolerance of ± 30 ppm, fragment mass tolerance of ± 0.5 Da, with ≥ 6 amino acid residues and only “unique plus razor peptides” that belong to a protein were chosen⁹¹. For limiting a certain number of peak matches by chance, a target-decoy-based FDR for peptide and protein identification was set to 0.01. Carbamidomethylation of cysteine was set as a fixed modification, while protein N-terminal acetylation and oxidation of methionine were defined as variable modifications, enzyme: trypsin and maximum number of missed cleavages: 2. The output of the generated “proteingroups.txt” data from the MaxQuant analysis was utilized for subsequent functional annotation and pathway analysis.

The GO functional annotation analysis of identified proteins was carried out with three different bioinformatics tools. These analyses allowed elucidation of the different functions and processes in which the identified and validated proteins would be putatively involved. Three independent sets of ontology were used in the annotation: “the molecular function”, “the biological processes”, in which the proteins participate, and their “cellular component”. Proteins without similarity to database entries were not considered for collation. First, the IPA was used for interpreting the GOCC terms, molecule types and PPI networks associated with the identified proteins. Top canonical pathways involving in the vasoactivity of the identified sPCA proteins were presented, along with a p -value calculated using Fisher’s exact test. Next, the molecular interactions networks between proteins associated with top diseases and functions were reported by the PANTHER classification system (version 11.0, released on the 15th July 2016), which includes 13096 protein families with 78442 functionally distinct protein subfamilies⁹⁵. Finally, DAVID tool was used for interpreting the GOBP and GOMF terms of the identified sPCA proteins that could not be specifically dissected employing IPA^{96,97}. The protein list was uploaded into DAVID and searched for enrichment for GOBP and GOMF terms, and the results were filtered based on threshold count ≥ 2 and P values < 0.05 .

References

1. Belotti, F. *et al.* Ophthalmic artery originating from the anterior cerebral artery: anatomo-radiological study, histological analysis, and literature review. *Neurosurg Rev* **39**, 483–493 (2016).
2. Cullen, J. Ischaemic Optic Neuropathy–Non Arteritic/NA-AION. *Optom Open Access* **1**, 1–3 (2016).
3. Liu, Q. & Rhoton, A. L. Jr. Middle meningeal origin of the ophthalmic artery. *Neurosurgery* **49**, 401–406 (2001).
4. Cioffi, G. A. Three common assumptions about ocular blood flow and glaucoma. *Surv Ophthalmol* **45**, S325–S331 (2001).
5. Fick, C. M. & Dubielzig, R. R. Short posterior ciliary artery anatomy in normal and acutely glaucomatous dogs. *Vet Ophthalmol* **19**, 43–49 (2016).
6. Hayreh, S. S. Posterior ciliary artery circulation in health and disease: the Weisenfeld lecture. *Invest Ophthalmol Vis Sci* **45**, 749–757 (2004).
7. Zeitz, O. *et al.* Glaucoma progression is associated with decreased blood flow velocities in the short posterior ciliary artery. *Brit J Ophthalmol* **90**, 1245–1248 (2006).
8. Zeitz, O. *et al.* Influence of oxygen free radicals on the tone of ciliary arteries: a model of vasospasms of ocular vasculature. *Graefes Arch Clin Exp Ophthalmol* **245**, 1327–1333 (2007).
9. Lam, D. *et al.* Glaucoma: Today and Tomorrow. *Asia Pac J Ophthalmol (Phila)* **5**, 2–4 (2016).
10. Mayama, C. & Araie, M. Effects of antiglaucoma drugs on blood flow of optic nerve heads and related structures. *Jpn J Ophthalmol* **57**, 133–149 (2013).
11. Quigley, H. A. & Broman, A. T. The number of people with glaucoma worldwide in 2010 and 2020. *Br J Ophthalmol* **90**, 262–267 (2006).
12. Tham, Y. C. *et al.* Global Prevalence of Glaucoma and Projections of Glaucoma Burden through 2040 A Systematic Review and Meta-Analysis. *Ophthalmology* **121**, 2081–2090 (2014).
13. Lee, M. S., Grossman, D., Arnold, A. C. & Sloan, F. A. Incidence of Nonarteritic Anterior Ischemic Optic Neuropathy: Increased Risk Among Diabetic Patients. *Ophthalmology* **118**, 959–963 (2011).
14. Patil, M., Ganger, A. & Saxena, R. Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)—A Brief Review. *OJOPh* **6**, 158–163 (2016).
15. Pasquale, L. R. Vascular and autonomic dysregulation in primary open-angle glaucoma. *Curr Opin Ophthalmol* **27**, 94–101 (2016).
16. Siesky, B. A., Harris, A., Amireskandari, A. & Marek, B. Glaucoma and ocular blood flow: an anatomical perspective. *Expert Rev Ophthalmol* **7**, 325–340 (2012).
17. Costa, V. P. *et al.* Ocular perfusion pressure in glaucoma. *Acta Ophthalmol* **92**, e252–266 (2014).

18. Buckley, C. H., Hadoke, P. W. F. & O'Brien, C. J. Use of isolated ocular arteries *in vitro* to define the pathology of vascular changes in glaucoma. *Brit J Ophthalmol* **81**, 599–607 (1997).
19. Nita, M. & Grzybowski, A. The Role of the Reactive Oxygen Species and Oxidative Stress in the Pathomechanism of the Age-Related Ocular Diseases and Other Pathologies of the Anterior and Posterior Eye Segments in Adults. *Oxid Med Cell Longev* **2016**, 1–23 (2016).
20. Schmidt, K. G., Klingmuller, V., Gouveia, S. M., Osborne, N. N. & Pillunat, L. E. Short posterior ciliary artery, central retinal artery, and choroidal hemodynamics in brimonidine-treated primary open-angle glaucoma patients. *Am J Ophthalmol* **136**, 1038–1048 (2003).
21. Fernandes, K. A. *et al.* Using genetic mouse models to gain insight into glaucoma: Past results and future possibilities. *Exp Eye Res* **141**, 42–56 (2015).
22. Nickells, R. W. & Pelzel, H. R. Tools and resources for analyzing gene expression changes in glaucomatous neurodegeneration. *Exp Eye Res* **141**, 99–110 (2015).
23. Ruiz-Ederra, J. *et al.* The pig eye as a novel model of glaucoma. *Exp Eye Res* **81**, 561–569 (2005).
24. Lunney, J. K. Advances in swine biomedical model genomics. *Int J Biol Sci* **3**, 179–184 (2007).
25. Prather, R. S., Lorson, M., Ross, J. W., Whyte, J. J. & Walters, E. Genetically engineered pig models for human diseases. *Annu Rev Anim Biosci* **1**, 203–219 (2013).
26. Sanchez, I., Martin, R., Ussa, F. & Fernandez-Bueno, I. The parameters of the porcine eyeball. *Graefes Arch Clin Exp Ophthalmol* **249**, 475–482 (2011).
27. Galougahi, K. K., Ashley, E. A. & Ali, Z. A. Redox regulation of vascular remodeling. *Cell Mol Life Sci* **73**, 349–363 (2016).
28. Regent, A. *et al.* Proteomic analysis of vascular smooth muscle cells in physiological condition and in pulmonary arterial hypertension: Toward contractile versus synthetic phenotypes. *Proteomics* **16**, 2637–2649 (2016).
29. Harburger, D. S. & Calderwood, D. A. Integrin signalling at a glance. *J Cell Sci* **122**, 159–163 (2009).
30. Morrison, J. C. Integrins in the optic nerve head: potential roles in glaucomatous optic neuropathy (an American Ophthalmological Society thesis). *Trans Am Ophthalmol Soc* **104**, 453–477 (2006).
31. Giancotti, F. G. & Ruoslahti, E. Integrin signaling. *Science* **285**, 1028–1032 (1999).
32. Mousa, S. A. Integrins as novel drug discovery targets: potential therapeutic and diagnostic implications. *Emerging Therapeutic Targets* **4**, 143–153 (2000).
33. Lehoux, S. & Tedgui, A. Cellular mechanics and gene expression in blood vessels. *J Biomech* **36**, 631–643 (2003).
34. Atan, N. A. D., Yekta, R. F., Nejad, M. R. & Nikzamir, A. Pathway and Network Analysis in Primary Open Angle Glaucoma. *JPS* **5**, 92–101 (2014).
35. Elner, S. G. & Elner, V. M. The integrin superfamily and the eye. *Invest Ophthalmol Vis Sci* **37**, 696–701 (1996).
36. Filla, M. S., Faralli, J. A., Peotter, J. L. & Peters, D. M. The role of integrins in glaucoma. *Exp Eye Res* (2016).
37. Clark, E. A. & Brugge, J. S. Integrins and signal transduction pathways: the road taken. *Science* **268**, 233–239 (1995).
38. Clark, E. A., King, W. G., Brugge, J. S., Symons, M. & Hynes, R. O. Integrin-mediated signals regulated by members of the rho family of GTPases. *J Cell Biol* **142**, 573–586 (1998).
39. Park-Windhol, C. & D'Amore, P. A. Disorders of Vascular Permeability. *Annu Rev Pathol* **11**, 251–281 (2016).
40. Balda, M. S. & Matter, K. Tight junctions as regulators of tissue remodelling. *Curr Opin Cell Biol* **42**, 94–101 (2016).
41. Sawada, N. *et al.* Tight junctions and human diseases. *Med Electron Microsc* **36**, 147–156 (2003).
42. Terry, S., Nie, M., Matter, K. & Balda, M. S. Rho signaling and tight junction functions. *Physiology (Bethesda)* **25**, 16–26 (2010).
43. Rolfe, B. E., Worth, N. F., World, C. J., Campbell, J. H. & Campbell, G. R. Rho and vascular disease. *Atherosclerosis* **183**, 1–16 (2005).
44. Hirata, K. *et al.* Involvement of rho p21 in the GTP-enhanced calcium ion sensitivity of smooth muscle contraction. *J Biol Chem* **267**, 8719–8722 (1992).
45. Worth, N. F., Campbell, G. R., Campbell, J. H. & Rolfe, B. E. Rho expression and activation in vascular smooth muscle cells. *Cell Motil Cytoskeleton* **59**, 189–200 (2004).
46. Bond, L. M., Sellers, J. R. & McKerracher, L. Rho kinase as a target for cerebral vascular disorders. *Future Med Chem* **7**, 1039–1053 (2015).
47. Hervé, J. C. & Bourmeyster, N. Rho GTPases at the crossroad of signaling networks in mammals. *Small GTPases* **6**, 43–48 (2015).
48. Nunes, K. P., Rigsby, C. S. & Webb, R. C. RhoA/Rho-kinase and vascular diseases: what is the link? *Cell Mol Life Sci* **67**, 3823–3836 (2010).
49. Wang, J., Liu, X. & Zhong, Y. Rho/Rho-associated kinase pathway in glaucoma (Review). *Int J Oncol* **43**, 1357–1367 (2013).
50. Anderson, D. R. Introductory comments on blood flow autoregulation in the optic nerve head and vascular risk factors in glaucoma. *Surv Ophthalmol* **43** Suppl 1, S5–9 (1999).
51. Chung, H. S. *et al.* Vascular aspects in the pathophysiology of glaucomatous optic neuropathy. *Surv Ophthalmol* **43** Suppl 1, S43–50 (1999).
52. Flammer, J. *et al.* The impact of ocular blood flow in glaucoma. *Prog Retin Eye Res* **21**, 359–393 (2002).
53. Bridges, D. & Moorhead, G. B. 14-3-3 proteins: a number of functions for a numbered protein. *Sci STKE* **2004**, re10 (2004).
54. Zhao, J., Meyerkord, C. L., Du, Y., Khuri, F. R. & Fu, H. 14-3-3 proteins as potential therapeutic targets. *Semin Cell Dev Biol* **22**, 705–712 (2011).
55. Aghazadeh, Y. & Papadopoulos, V. The role of the 14-3-3 protein family in health, disease, and drug development. *Drug Discov Today* **21**, 278–287 (2016).
56. Autieri, M. V. Inducible expression of the signal transduction protein 14-3-3 γ in injured arteries and stimulated human vascular smooth muscle cells. *Exp Mol Pathol* **76**, 99–107 (2004).
57. Jin, J. *et al.* Proteomic, functional, and domain-based analysis of *in vivo* 14-3-3 binding proteins involved in cytoskeletal regulation and cellular organization. *Curr Biol* **14**, 1436–1450 (2004).
58. Yacoubian, T. A. *et al.* Differential neuroprotective effects of 14-3-3 proteins in models of Parkinson's disease. *Cell Death Dis* **1**, e2, doi: 10.1038/cddis.2009.4 (2010).
59. Jeon, S. J., Sung, J. H. & Koh, P. O. Hyperglycemia decreases expression of 14-3-3 proteins in an animal model of stroke. *Neurosci Lett* **626**, 13–18 (2016).
60. Demasi, M. & Laurindo, F. R. Physiological and pathological role of the ubiquitin-proteasome system in the vascular smooth muscle cell. *Cardiovasc Res* **95**, 183–193 (2012).
61. Majesky, M. W. Developmental basis of vascular smooth muscle diversity. *Arterioscler Thromb Vasc Biol* **27**, 1248–1258 (2007).
62. Yang, X., Luo, C., Cai, J., Pierce, W. M. & Tezel, G. Phosphorylation-dependent interaction with 14-3-3 in the regulation of bad trafficking in retinal ganglion cells. *Invest Ophthalmol Vis Sci* **49**, 2483–2494 (2008).
63. Wang, D. Y. *et al.* Global gene expression changes in rat retinal ganglion cells in experimental glaucoma. *Invest Ophthalmol Vis Sci* **51**, 4084–4095 (2010).
64. Elliott, P. J. & Ross, J. S. The proteasome: a new target for novel drug therapies. *Am J Clin Pathol* **116**, 637–646 (2001).
65. McNaught, K. S., Belizaire, R., Isacson, O., Jenner, P. & Olanow, C. W. Altered proteasomal function in sporadic Parkinson's disease. *Exp Neurol* **179**, 38–46 (2003).
66. Herrmann, J. *et al.* Primary proteasome inhibition results in cardiac dysfunction. *Eur J Heart Fail* **15**, 614–623 (2013).
67. Oikawa, T. *et al.* The proteasome is involved in angiogenesis. *Biochem Bioph Res Co* **246**, 243–248 (1998).

68. Walsh, D. A. & Pearson, C. I. Angiogenesis in the pathogenesis of inflammatory joint and lung diseases. *Arthritis Res* **3**, 147–153 (2001).
69. Fernandes, D. C., Manoel, A. H., Wosniak, J. Jr. & Laurindo, F. R. Protein disulfide isomerase overexpression in vascular smooth muscle cells induces spontaneous preemptive NADPH oxidase activation and Nox1 mRNA expression: effects of nitrosothiol exposure. *Arch Biochem Biophys* **484**, 197–204 (2009).
70. Gellert, M., Hanschmann, E. M., Lepka, K., Berndt, C. & Lillig, C. H. Redox regulation of cytoskeletal dynamics during differentiation and de-differentiation. *Biochim Biophys Acta* **1850**, 1575–1587 (2015).
71. Meinke, P., Makarov, A., Thanh, P., Sadurska, D. & Schirmer, E. Nucleoskeleton dynamics and functions in health and disease. *Cell Health Cytoskeleton* **7**, 55–69 (2015).
72. Zou, C., La Bonte, L. R., Pavlov, V. I. & Stahl, G. L. Murine hyperglycemic vasculopathy and cardiomyopathy: whole-genome gene expression analysis predicts cellular targets and regulatory networks influenced by mannose binding lectin. *Front Immunol* **3**, 1–9, doi: 10.3389/fimmu.2012.00015 (2012).
73. Hein, S., Kostin, S., Heling, A., Maeno, Y. & Schaper, J. The role of the cytoskeleton in heart failure. *Cardiovasc Res* **45**, 273–278 (2000).
74. Orgul, S., Gugleta, K. & Flammer, J. Physiology of perfusion as it relates to the optic nerve head. *Surv Ophthalmol* **43**, S17–S26 (1999).
75. Yu, D. Y. *et al.* Agonist response of human isolated posterior ciliary artery. *Invest Ophthalmol Vis Sci* **33**, 48–54 (1992).
76. Pache, M. *et al.* Extraocular blood flow and endothelin-1 plasma levels in patients with multiple sclerosis. *Eur Neurol* **49**, 164–168 (2003).
77. Zouki, C., Baron, C., Fournier, A. & Filep, J. G. Endothelin-1 enhances neutrophil adhesion to human coronary artery endothelial cells: role of ETA receptors and platelet-activating factor. *Brit J Pharmacol* **127**, 969–979 (1999).
78. Wess, J., Eglén, R. M. & Gautam, D. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. *Nat Rev Drug Discov* **6**, 721–733 (2007).
79. Tzavara, E. T. *et al.* Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2/M4 muscarinic receptor knockout mice. *Mol Psychiatry* **8**, 673–679 (2003).
80. Zhang, W. L. *et al.* Characterization of central inhibitory muscarinic autoreceptors by the use of muscarinic acetylcholine receptor knock-out mice. *J Neurosci* **22**, 1709–1717 (2002).
81. Badhwar, A., Stanimirovic, D. B., Hamel, E. & Haqqani, A. S. The proteome of mouse cerebral arteries. *J Cereb Blood Flow Metab* **34**, 1033–1046 (2014).
82. Miao, Y. *et al.* Acetylcholine Inhibits Tumor Necrosis Factor α Activated Endoplasmic Reticulum Apoptotic Pathway via EGFR-P13K Signaling in Cardiomyocytes. *J Cell Physiol* **230**, 767–774 (2015).
83. Haefliger, I. O., Flammer, J. & Luscher, T. F. Heterogeneity of endothelium-dependent regulation in ophthalmic and ciliary arteries. *Invest Ophthalmol Vis Sci* **34**, 1722–1730 (1993).
84. Ninomiya, H. & Inomata, T. Microvascular anatomy of the pig eye: scanning electron microscopy of vascular corrosion casts. *J Vet Med Sci* **68**, 1149–1154 (2006).
85. Yao, K., Tschudi, M., Flammer, J. & Luscher, T. F. Endothelium-dependent regulation of vascular tone of the porcine ophthalmic artery. *Invest Ophthalmol Vis Sci* **32**, 1791–1798 (1991).
86. Perumal, N., Funke, S., Pfeiffer, N. & Grus, F. H. Characterization of lacrimal proline-rich protein 4 (PRR4) in human tear proteome. *Proteomics* **14**, 1698–1709 (2014).
87. Shevchenko, A., Tomas, H., Havli, J., Olsen, J. V. & Mann, M. In-gel digestion for mass spectrometric characterization of proteins and proteomes. *Nat Protoc* **1**, 2856–2860 (2006).
88. Perumal, N., Funke, S., Wolters, D., Pfeiffer, N. & Grus, F. H. Characterization of human reflex tear proteome reveals high expression of lacrimal proline-rich protein 4 (PRR4). *Proteomics* **15**, 3370–3381 (2015).
89. Perumal, N., Funke, S., Pfeiffer, N. & Grus, F. H. Proteomics analysis of human tears from aqueous-deficient and evaporative dry eye patients. *Sci Rep* **6**, 29629, doi: 10.1038/srep29629 (2016).
90. Olsen, J. V. *et al.* Parts per million mass accuracy on an Orbitrap mass spectrometer via lock mass injection into a C-trap. *Mol Cell Proteomics* **4**, 2010–2021 (2005).
91. Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. *Nat Biotechnol* **26**, 1367–1372 (2008).
92. Luber, C. A. *et al.* Quantitative proteomics reveals subset-specific viral recognition in dendritic cells. *Immunity* **32**, 279–289 (2010).
93. Cox, J. *et al.* Accurate Proteome-wide Label-free Quantification by Delayed Normalization and Maximal Peptide Ratio Extraction, Termed MaxLFQ. *Mol Cell Proteomics* **13**, 2513–2526 (2014).
94. Cox, J. *et al.* Andromeda: A Peptide Search Engine Integrated into the MaxQuant Environment. *J Proteome Res* **10**, 1794–1805 (2011).
95. Mi, H., Poudel, S., Muruganujan, A., Casagrande, J. T. & Thomas, P. D. PANTHER version 10: expanded protein families and functions, and analysis tools. *Nucleic Acids Res* **44**, D336–342 (2016).
96. Huang, D. W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc* **4**, 44–57 (2009).
97. Huang, D. W., Sherman, B. T. & Lempicki, R. A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. *Nucleic Acids Res* **37**, 1–13 (2009).

Acknowledgements

Dr. Manicam's work is supported by the Internal University Research Funding (Stufe 1) from the University Medical Centre of the Johannes Gutenberg University Mainz and supported in part by a grant from the Ernst und Berta Grimmke-Stiftung.

Author Contributions

C.M. conceived and designed the study, performed the experiments, analysed and interpreted the data, and wrote the manuscript. N. Perumal designed the study, analysed and interpreted the data, and helped to write the manuscript. FHG contributed essential materials and analysis tools, and helped draft the manuscript. N. Pfeiffer contributed essential materials and analysis tools, and helped draft the manuscript. A.G. participated in the design of the study, contributed essential materials and tools, and helped draft the manuscript. All authors were involved in the discussion of results, critical reading and final approval of the manuscript.

Additional Information

Supplementary information accompanies this paper at <http://www.nature.com/srep>

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Manicam, C. *et al.* First insight into the proteome landscape of the porcine short posterior ciliary arteries: Key signalling pathways maintaining physiologic functions. *Sci. Rep.* **6**, 38298; doi: 10.1038/srep38298 (2016).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2016